$0.94
+0.06 (+6.93%)
Open$0.90
Previous Close$0.88
Day High$0.97
Day Low$0.88
52W High$2.22
52W Low$0.55
Volume—
Avg Volume240.7K
Market Cap11.52M
P/E Ratio—
EPS$-1.97
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+3,732.1% upside
Current
$0.94
$0.94
Target
$36.06
$36.06
$23.45
$36.06 avg
$38.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 534.9K | 1.10M | 1.13M |
| Net Income | -23,583,986 | 89.2K | 117.7K |
| Profit Margin | -4,409.1% | 8.1% | 10.4% |
| EBITDA | -24,585,164 | 177.4K | 182.1K |
| Free Cash Flow | — | 70.9K | 72.7K |
| Rev Growth | — | +5.3% | -7.0% |
| Debt/Equity | — | 0.17 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |